Aims: Prescribing drug treatment for the management of hyperemesis gravidarum (HG), the most severe form of nausea and vomiting in pregnancy, remains controversial. Since most manufacturers do not recommend prescribing antiemetics during pregnancy, little is known regarding which treatments are most prevalent among pregnant patients. Here, we report for the first time, evidence of actual treatments prescribed in English hospitals.
| INTRODUC TI ON
Hyperemesis gravidarum (HG), the most severe form of nausea and vomiting in pregnancy (NVP), is characterised by persistent vomiting resulting in fluid and electrolyte derangement, weight loss, and nutritional deficiencies severe enough to require medical attention. 1 The reported occurrence of HG varies between 0.3% and 2% of pregnancies worldwide. 2 HG is the commonest cause of hospital admission in pregnancy, after preterm labour, in the UK and the United States, 3, 4 and the costs associated with the burden of managing HG are significant worldwide. [5] [6] [7] A wide range of therapeutic agents are used in the management of HG internationally. [7] [8] [9] In the UK, the 2016 Royal
College of Obstetricians and Gynaecologists (RCOG) Green Top Guidelines 10 recommend a stepwise prescribing system where the use of antihistamines and phenothiazines are defined as firstline treatment; dopamine and serotonin antagonists as secondline treatments, followed by steroids as third-line treatment; the use of pyridoxine is discouraged. Although several systematic reviews [11] [12] [13] provide evidence for the safety of antihistamines and dopamine antagonists used in pregnancy, manufacturers worldwide remain cautious and do not recommend their use antenatally, leaving prescribing to the discretion of the health professional when they consider the potential benefits outweigh the risks. In the light of this, it is not yet known which drug treatments are most commonly used to treat HG, or whether and how current clinical guidelines are followed by health professionals.
An understanding of the common clinical practice adopted by health professionals could help increase confidence in doctors'
prescribing, highlight potential weaknesses of the actual management and therefore help improve the service offered to women affected by HG.
English Maternity Hospital Episode Statistics provide important information on HG admissions for almost all pregnancies in
England, 2, 14 however, they currently have no information on medications prescribed. To determine which drugs are most commonly prescribed at discharge for the management of HG in secondary care, we used anonymised clinical data from women admitted to the Nottingham University Hospitals (NUH) National Health Service
Trust. We evaluated whether prescribing reflected national or local guidelines and whether prescribing differed based on women's characteristics, such as age and ethnicity.
| ME THODS

| Study population
This study used anonymised clinical data from NUH, which is one of the largest National Health Service (NHS) Hospital Trusts in England, accounting for roughly 10 000 births a year. 15 An NHS hospital trust is a secondary care organisation, typically consisting of 1-3 collectively managed hospitals that cover a geographical catchment area for the local population. What's known
• Local and national guidelines on hyperemesis gravidarum (HG) management recommend a stepwise approach to treatment medications based on the level of HG severity.
• Manufacturers worldwide remain cautious and do not recommend prescribing most antiemetics during pregnancy.
What's new
• Drug management of HG in a large English hospital trust reflects national guidelines.
• Discharge prescriptions indicated that stepwise use of treatments based on HG severity was being used uni- 
| Analysis of drug prescribing
We plotted the occurrence of HG admissions by gestational week to assess that the distribution followed the recognised presentation of HG across pregnancy. For HG admissions with recorded drug prescriptions at discharge, we described the prescribing prevalence for each of the six drug classes at first and subsequent HG admissions.
Prescribing prevalence at first admission was assessed separately for women who only had one admission and women who went on to be readmitted. We then described the prescribing prevalence of individual drugs by admission according to whether they were first-, second-, third-, or fourth-line treatment in the NUH clinical guidelines. 18 We included separate prevalence figures to show whether drug classes (or individual drugs) were prescribed alone or in combination.
To assess whether stepwise prescribing according to the guidelines was being used universally for all women admitted with HG, we compared proportions prescribed each line of treatment across each maternal characteristic using chi-squared or Fisher's exact tests.
| RE SULTS
There were 51 613 pregnancies in the NUH pregnancy cohort be- 
| Drug prescribing on discharge
There were 1037 admissions with a primary diagnosis of HG, of which 530 (51%) had records for prescribed drugs at discharge.
Antihistamines, prescribed either alone or in combination were the most common drug class prescribed at discharge from first HG admissions, followed by serotonin antagonists (Table 2) .
Antihistamines prescriptions were less frequent for subsequent admissions but they were still the most commonly prescribed drug class alone. Dopamine and Serotonin antagonists were most commonly prescribed in combination at discharge from subsequent admissions. Prescribing prevalence of phenothiazines was similar following first and subsequent admissions. Vitamins were prescribed on discharge more often in subsequent admissions, while steroids were used exclusively at subsequent admissions. In the context of the NUH guideline for HG management, Table 3 shows the frequency of discharge prescriptions according to each line of treatment. While promethazine was very rarely prescribed, cyclizine was generally the most common first-line drug, prescribed alone or in combination. Most first admissions had a discharge prescription for cyclizine (79% of those among women admitted only once and 83%
of those for women with multiple admissions) as did subsequent admissions (9% prescribed alone and 53% in combination) ( Table 3 ). In terms of second-line treatments, prochlorperazine was prescribed less often than metoclopramide at discharge. The use of prochlorperazine was prescribed similarly at first and subsequent admissions, whereas discharge prescribing of metoclopramide was more common in subsequent admissions. Ondansetron, which is recommended as thirdline treatment in the NUH guidance, was in fact more common than metoclopramide for first admissions both alone and in combination with other drugs. It was also prescribed more often for discharge from subsequent admissions compared with first admissions.
The only prescribed steroid was prednisolone and, in line with the NUH guidelines, was only prescribed at discharge from readmission.
Thiamine was more frequently prescribed following readmissions compared with first admissions, in line with the NUH guidelines, while high dose of folic acid was prescribed similarly following first or subsequent admissions. There were no prescriptions for chlorpromazine, hydrocortisone, or methylprednisolone; however, these drugs are usually given intravenously and therefore not prescribed at discharge. For first admissions, the prescribing prevalence of cyclizine, prochlorperazine, and ondansetron were considerably higher, particularly in combination, among women who went on to have subsequent admissions, compared with women admitted only once. The most commonly prescribed drug combinations were cyclizine with ondansetron, metoclopramide with 
Discharge prescriptions indicated that stepwise use of treatments based on HG severity was being used universally (Table 4) .
First-line therapy was prescribed most often; however, third-line therapy (ondansetron) was prescribed more frequently than secondline therapy. The use of first-, second-, and subsequent-line treatments showed little variation by maternal characteristics as shown in Table 4 where the percentages are calculated over the total for each maternal characteristic value. The use of first-line therapy was slightly more common in women with recorded mental health problems. Younger women were slightly less likely to receive discharge prescriptions for second-line treatments, although there were no statistically significant differences for any other lines of treatment according to age. Lower BMI and non-smoking were associated with slightly higher use of third-line therapy. Fourth-line treatment did
show variation according to certain maternal characteristics, such as deprivation and smoking status; however, it was very rarely prescribed at discharge (only 21 admissions) so statistical power was low for assessing differences. Thiamine was more commonly prescribed in women with Asian or other ethnicity recorded, and less commonly prescribed in women with previous mental health problems.
| D ISCUSS I ON
| Main findings
At discharge from HG admission, drugs were most often prescribed in combination rather than alone. The drugs most frequently prescribed, in order of occurrence, were cyclyzine (first-line treatment), ondansetron (third-line treatment), metoclopramide and prochlorperazine (second-line treatments). In line with local hospital guidelines prednisolone (fourth-line treatment) was prescribed only at discharge from readmission. While thiamine was most frequently prescribed following readmission, high dose of folic acid was equally used at first and subsequent admissions. Prescribing patterns were generally very similar across all women, regardless of differences in maternal characteristics. Only prescribing of third-and fourthline treatments, for the most severe presentations of HG, showed some variation by women's characteristics; these were more likely prescribed to women with asthma, those who were underweight, or non-smokers. 
| Strengths and limitations
| Comparisons with previous studies
We found a prevalence of 1.7% for being admitted to hospital for HG during pregnancy (1.4% among pregnancies overall including those TA B L E 4 Maternal characteristics by NUH line of treatment prescribed at discharge for 530 hyperemesis gravidarum admissions with missing gestational age) which was similar to figures from other international studies [21] [22] [23] ranging between 0.3% and 1.5%, and our previous study using national data. 24 We found a median length of hospital stay of 2 days for any admission, within the 1.8-6 day range reported in the literature. [25] [26] [27] The length of hospital stay is linked to the effectiveness of the specific treatment offered during the cur- Only a few studies have so far described maternal characteristics of women by antiemetic use. In general, we found modest variation in prescribing according to women's characteristics, however, asthmatic women were more likely to be prescribed corticosteroids; it is possible that some of this use was related to asthma which is slightly more common in women presenting with HG.
Thiamine was more common in women with Black or Asian ethnicity, who are groups with particularly high risks of HG. 2 We found that older women were more likely to be prescribed phenothiazines and dopamine antagonists while women who were underweight or non-smokers were more likely to be prescribed serotonin antagonists, in contrast with two previous North American studies from 2013 30 and 2014, 31 which both reported a higher usage of antihistamines among older women. An Australian study reported that serotonin antagonists were more likely prescribed to nonsmoking women in agreement with our results. 23 The same study also found they were used more for women in higher socioeconomic groups and Caucasian women, in contrast to our study. 32 To the best of our knowledge, no study to date has assessed whether hospital prescribing for HG is compliant with national or local guidelines in England.
| CON CLUS IONS
The 
